Clinically, the subtypes are divided into luminal, HER2-enriched, and triple-negative breast cancer (TNBC) based on immunohistochemical staining of the estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) status [2–4]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.